BioMarin Reports Q4 Earnings

Rare disease drugmaker beats Wall Street expectations on revenue and earnings

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

BioMarin Pharmaceutical Inc. reported a fourth-quarter loss of $46.6 million, or $0.24 per share, after reporting a profit in the same period a year earlier. However, the company's adjusted earnings of $0.46 per share and revenue of $874.6 million both beat Wall Street forecasts. For the full year, BioMarin reported a profit of $348.9 million, or $1.80 per share, on revenue of $3.22 billion.

Why it matters

BioMarin is a leading rare disease drugmaker, so its quarterly and annual financial results provide insights into the performance of this specialized pharmaceutical segment. The company's ability to exceed analyst expectations on both the top and bottom lines suggests strong underlying demand for its rare disease treatments.

The details

BioMarin reported a Q4 loss of $46.6 million, or $0.24 per share, compared to a profit in the year-ago quarter. However, the company's adjusted earnings of $0.46 per share beat the average analyst estimate of $0.25 per share. Revenue in Q4 came in at $874.6 million, topping the $829.7 million that analysts had projected. For the full year, BioMarin reported a profit of $348.9 million, or $1.80 per share, on revenue of $3.22 billion.

  • BioMarin reported its Q4 and full-year 2025 financial results on February 23, 2026.

The players

BioMarin Pharmaceutical Inc.

A biopharmaceutical company that develops and commercializes therapies for rare genetic diseases.

Got photos? Submit your photos here. ›

The takeaway

BioMarin's ability to exceed Wall Street's expectations on both revenue and earnings in Q4 and for the full year 2025 demonstrates the strong demand for its rare disease treatments and the company's operational execution, even in a challenging economic environment.